1g9n image
Deposition Date 2000-11-25
Release Date 2000-12-27
Last Version Date 2024-11-06
Entry Detail
PDB ID:
1G9N
Title:
HIV-1 YU2 GP120 ENVELOPE GLYCOPROTEIN COMPLEXED WITH CD4 AND INDUCED NEUTRALIZING ANTIBODY 17B
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
2.90 Å
R-Value Free:
0.29
R-Value Work:
0.20
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:T-CELL SURFACE GLYCOPROTEIN CD4
Gene (Uniprot):CD4
Mutations:S184N, I185T
Chain IDs:B (auth: C)
Chain Length:185
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:ENVELOPE GLYCOPROTEIN GP120
Gene (Uniprot):env
Mutations:VARIABLE LOOPS SUBSTITUTED
Chain IDs:A (auth: G)
Chain Length:313
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:ANTIBODY 17B, HEAVY CHAIN
Chain IDs:D (auth: H)
Chain Length:229
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:ANTIBODY 17B, LIGHT CHAIN
Chain IDs:C (auth: L)
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
ASN A ASN GLYCOSYLATION SITE
Ligand Molecules
Primary Citation
Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.
Structure Fold.Des. 8 1329 1339 (2000)
PMID: 11188697 DOI: 10.1016/S0969-2126(00)00547-5

Abstact

BACKGROUND: The gp120 exterior envelope glycoprotein of HIV-1 binds sequentially to CD4 and chemokine receptors on cells to initiate virus entry. During natural infection, gp120 is a primary target of the humoral immune response, and it has evolved to resist antibody-mediated neutralization. We previously reported the structure at 2.5 A of a gp120 core from the HXBc2 laboratory-adapted isolate in complex with a 2 domain fragment of CD4 and the antigen binding fragment of a human antibody. This revealed atomic details of gp120-receptor interactions and suggested multiple mechanisms of immune evasion. RESULTS: We have now extended the HXBc2 structure in P222, crystals to 2.2 A. The enhanced resolution enabled a more accurate modeling of less-well-ordered regions and provided conclusive identification of the density in the central cavity at the crux of the gp120-CD4 interaction as isopropanol from the crystallization medium. We have also determined the structure of a gp120 core from the primary clinical HIV-1 isolate, YU2, in the same ternary complex but in a C2 crystal lattice. Comparisons of HXBc2 and YU2 showed that while CD4 binding was rigid, portions of the gp120 core were conformationally flexible; overall differences were minor, with sequence changes concentrated on a surface expected to be exposed on the envelope oligomer. CONCLUSIONS: Despite dramatic antigenic differences between primary and laboratory-adapted HIV-1, the gp120 cores from these isolates are remarkably similar. Taken together with chimeric substitution and sequence analysis, this indicates that neutralization resistance is specified by quaternary interactions involving the major variable loops and thus affords a mechanism for viral adaptation. Conservation of the central cavity suggests the possibility of therapeutic inhibitors. The structures reported here extend in detail and generality our understanding of the biology of the gp120 envelope glycoprotein.

Legend

Protein

Chemical

Disease

Primary Citation of related structures